Targeted, System-Matched Probiotics:
Design and Evidence Approach

1. The problem with kitchen-sink probiotics

The probiotic market is dominated by broad-spectrum blends positioned for general wellness. The strain-specificity principle — that a probiotic's effect depends on the specific strain and the specific indication — is well established in the literature.^1,2 Yet a fixed blend of a dozen organisms offers no mechanism to match strains to an individual's actual complaint, and it dilutes the per-strain dose across many organisms.

GoodOnes inverts that: identify the strain patterns that recur across thousands of microbiome profiles, and assemble a focused formula for one body system at a studied dose. Less, matched more precisely.

2. The dataset behind the design

Flore has sequenced 23,447 microbiomes through its longitudinal program. We use that dataset to study aggregate microbiome patterns — which strains and combinations recur across people grouped by body system — and those patterns inform which strains anchor each GoodOnes formula. The dataset is a design input; it is not a controlled trial of the finished products.

This distinction matters, and we state it plainly: aggregate pattern-mining tells you which strains are worth building around. It does not, on its own, prove that a given finished formula resolves a given symptom. That requires controlled study (§6).

3. How a GoodOne is built

3.1 The Universal Core — data-derived

Every adult formula is built on a shared core of three strains — Bifidobacterium breve, Lactiplantibacillus plantarum, and Lactobacillus rhamnosus. These were chosen because they recur across formulations for every body system in the dataset, which is why they anchor the line. CFU per strain is determined by formulation; dose justification is on file and available to practitioners and research partners on request.

3.2 System-matched formulas

On top of the core, each formula adds two strains chosen for one body system:

Genus and species are printed on every Supplement Facts label. The proprietary strain sub-identifier is masked on the public site as an RGO code; the full designation is available to practitioners and research partners on request.

3.3 Two ways to get there

Flore — algorithm-matched from an individual's own sequencing and survey data, direct-to-consumer. GoodOnes — provider-driven, adding clinician oversight, follow-up, and reformulation. GoodOnes is the fixed-price, no-test on-ramp to the same strain science.

4. The published research behind the strains

Each formula draws on published, third-party research on its constituent strains — for example, randomized controlled trials of specific Bifidobacterium strains for functional constipation, and psychobiotic studies of Lactiplantibacillus plantarum for mood under stress. These are studies of the strains, not of the finished GoodOnes formula. The specific citations (with PubMed IDs) for each formula are on file; a representative set is in the References below.

Flore's parent research includes a peer-reviewed study of its own custom synbiotic in autism (mSystems, ASM, 2024) — an open-label pilot study, not a randomized controlled trial. We describe it as exactly that.

5. Mechanism and rationale RATIONALE — mechanistic, not a proven outcome

• GI: Bifidobacterium fermentation of fiber to short-chain fatty acids supports motility and mucosal-barrier integrity.
• Mood: gut-brain-axis modulation of tryptophan metabolism and vagal signaling.
• Immune: gut-associated lymphoid tissue priming and secretory-IgA support.
• Joint: an anti-inflammatory rationale via the gut-immune axis.
• Focus & Calm: L. reuteri gut-vagus signaling — a rationale from preclinical and early human work; structure/function only.

These are mechanistic hypotheses that motivate the strain choices. They are not claims that any formula treats a condition.

6. What the evidence does not show — and what comes next

We think it is more useful to be clear about the limits than to over-claim:

• No finished-product RCTs yet. GoodOnes formulas have not been tested head-to-head against placebo in randomized controlled trials. Evidence to date is the published strain literature plus Flore's observational, self-reported program data.
• Observational data is not proof of cause. Many symptoms remit on their own; people who re-engage with a program skew toward those already improving. Any association is just that — an association.
• Individual results vary. A targeted strain at a studied dose is a reasonable, mechanism-led bet for the matched complaint — not a guarantee.

The natural next step for a design like this is prospective, controlled evaluation — placebo-controlled trials of the lead formulas with validated endpoints and microbiome biomarker sub-studies. Practitioner and research-collaborator inquiries are welcome at [email protected].

7. Why GoodOnes exists

Across Flore's personalized program, the leading reason people stopped was cost, not dissatisfaction. GoodOnes was built to answer that: a fixed-price, system-matched tier at $49 per bottle (Subscribe & Save from $44.10/mo), designed to preserve the strain-specificity principle without requiring a personalized subscription or a stool test. It is the accessible front door to the same strain science.

GoodOnes™ targeted probiotic formulas: realgoodones.com · Practitioner inquiries: realgoodones.com

Prefer to just ask? Talk to our concierge or take the 90-second quiz.